Alx Oncology Holdings Inc [NASDAQ: ALXO] jumped around 0.33 points on Monday, while shares priced at $0.97 at the close of the session, up 50.69%.
Alx Oncology Holdings Inc stock is now -62.37% down from its year-to-date (YTD) trading value. ALXO Stock saw the intraday high of $1.04 and lowest of $0.6601 per share. The company’s 52-week high price is 2.73, which means current price is +140.32% above from all time high which was touched on 01/08/25.
Compared to the average trading volume of 521.49K shares, ALXO reached a trading volume of 15872118 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Alx Oncology Holdings Inc [ALXO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALXO shares is $2.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXO stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Alx Oncology Holdings Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 06, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price from $12 to $2. The new note on the price target was released on December 19, 2024, representing the official price target for Alx Oncology Holdings Inc stock. Previously, the target price had yet another raise from $10 to $14, while Stifel kept a Hold rating on ALXO stock. On December 08, 2023, analysts increased their price target for ALXO shares from 8 to 18.
The Price to Book ratio for the last quarter was 0.81, with the Price to Cash per share for the same quarter was set at 1.48.
How has ALXO stock performed recently?
Alx Oncology Holdings Inc [ALXO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 58.00. With this latest performance, ALXO shares gained by 91.65% in over the last four-week period, additionally sinking by -11.74% over the last 6 months – not to mention a drop of -41.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALXO stock in for the last two-week period is set at 77.50, with the RSI for the last a single of trading hit 0.0930, and the three-weeks RSI is set at 0.0695 for Alx Oncology Holdings Inc [ALXO]. The present Moving Average for the last 50 days of trading for this stock 0.5395, while it was recorded at 0.7092 for the last single week of trading, and 0.9455 for the last 200 days.
Alx Oncology Holdings Inc (ALXO) Capital Structure & Debt Analysis
According to recent financial data for Alx Oncology Holdings Inc. ( ALXO), the Return on Equity (ROE) stands at -104.21%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -75.22%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Alx Oncology Holdings Inc’s Return on Invested Capital (ROIC) is -154.31%, showcasing its effectiveness in deploying capital for earnings.
Alx Oncology Holdings Inc (ALXO) Efficiency & Liquidity Metrics
Based on Alx Oncology Holdings Inc’s (ALXO) latest financial statements, the Debt-to-Equity Ratio is 0.25%, indicating its reliance on debt financing relative to shareholder equity.
Alx Oncology Holdings Inc (ALXO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Alx Oncology Holdings Inc. (ALXO) effectively leverages its workforce, generating an average of -$1457125.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.52% and a Quick Ratio of 4.52%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Alx Oncology Holdings Inc [ALXO]
With the latest financial reports released by the company, Alx Oncology Holdings Inc posted -0.58/share EPS, while the average EPS was predicted by analysts to be reported at -0.66/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.07. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALXO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Alx Oncology Holdings Inc go to 32.50%.
Insider trade positions for Alx Oncology Holdings Inc [ALXO]
There are presently around $68.66%, or 70.38%% of ALXO stock, in the hands of institutional investors. The top three institutional holders of ALXO stocks are: VENBIO PARTNERS LLC with ownership of 9.7 million shares, which is approximately 18.7145%. FMR LLC, holding 7.81 million shares of the stock with an approximate value of $$47.12 million in ALXO stocks shares; and FMR LLC, currently with $$25.45 million in ALXO stock with ownership which is approximately 8.1419%.
